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start sites. Increased expression of C/EBP has beenStriking it Rich by Data Mining
detected in breast cancer, ovarian tumors, and colo-
rectal tumors (reviewed in Zahnow, 2002). In contrast,
C/EBP null mice are refractory to Ras-mediated skin
tumorigenesis (Zhu et al., 2002). Thus, disruption of sig-In this issue of Cell, Lamb et al. have used a combina-
naling through C/EBP appears to contribute to malig-tion of molecular genetics, DNA microarray, and data
nant transformation.mining of human tumor expression databases to iden-
To provide independent evidence that supports thetify a cdk-independent mechanism by which the in-
role of C/EBP in the mechanism of cyclin D1 action,teraction of cyclin D1 with the transcription factor
Lamb et al. (2003) conducted a functional analysis ofC/EBP may mediate tumorigenesis.
target gene promoters using conventional transfection
assays. Cyclin D1-responsive regions were mapped inAlthough the protooncogene cyclin D1 is overexpressed
the promoters of six genes, including HSP70-2, whichin approximately 45% of breast cancers (Hui et al., 1996)
the original microarray analysis showed to be inducedas well as a broad range of other human tumor types,
with similar kinetics by both wild-type and mutant cyclinthe mechanisms through which cyclin D1 mediates its
D1. Consensus C/EBP binding sites were present ineffects on tumorigenesis have not yet been elucidated.
each of these promoters, and mutation of these sitesThe D-type cyclins represent a fundamental link be-
resulted in a higher basal activity. Surprisingly, thesetween signal transduction pathways and the cell cycle
results suggest that C/EBP acts as a constitutive re-machinery; thus, it has been suspected that cyclin/cdk
pressor of cyclin D1 targets and that cyclin D1 antago-complexes act not only as essential regulators of cell
nizes this repressor function. Additional support wasdivision, but are also responsible for the oncogenic ef-
provided through the use of a dominant-negative iso-fect of cyclin D1. However, several recent studies, in-
form of C/EBP, LIP, which is translated from the thirdcluding the analysis of cyclin D1-deficient mice, have
in-frame AUG and therefore lacks most of the amino-suggested that cyclin D1 may indeed have other activi-
terminal transactivation domain, but still contains theties separate and distinct from its role as a cdk regula-
DNA binding and leucine zipper dimerization domains.
tory subunit and regulator of Rb (reviewed in Coqueret,
LIP can recapitulate the effects of cyclin D1, suggesting
2002). Lamb et al. (2003) have now taken a molecular
an alternative mechanism of regulation of target gene
genetic approach to identify alternative cyclin D1 activi-
expression. The direct or indirect association of cyclin
ties by generating a mutant incapable of activating cdk4
D1 with C/EBP was demonstrated by coimmunopreci-
and then using DNA microarrays to screen for target
pitation experiments. Finally, the regulation of target
genes differentially activated by overexpression of this gene expression by cyclin D1 was abrogated in C/EBP
mutant in comparison with wild-type cyclin D1. Using null mammary epithelial cells, providing genetic evi-
this approach, they have identified an expression signa- dence for the importance of this interaction. Thus, by
ture for the putative cdk-independent function of cyclin integrating experimental and tumor expression data,
D1 in MCF-7 breast cancer cells and then validated these investigators have been able to provide novel in-
many of the target genes identified by RNase protection sights into proteins that function in a common pathway
assays in both MCF-7 and another breast cancer cell with cyclin D1 and may participate in its mechanism of
line, MDA-MB468. action, an approach heretofore used primarily in yeast.
In addition, these investigators have also used a more Several important questions are raised by these intri-
powerful and novel approach involving data mining to guing studies. First, by what mechanism does C/EBP
query the expression patterns of thousands of genes repress the expression of the cyclin D1 target genes
across 190 primary human tumors of 14 different histo- and second, how does the interaction with cyclin D1
logical types to determine if the biologically relevant counteract this repression? In order to answer these
cyclin D1 target genes were frequently coexpressed with questions, it will be critical to determine the occupancy
endogenous cyclin D1. Using the Kolmogorov-Smirnov of specific coactivators and corepressors on the cyclin
(KS) nonparametric rank statistic, Lamb et al. (2003) first D1 target promoters. Full-length C/EBP LAP1, whose
validated the set of 21 genes. Surprisingly, no E2F target translation is initiated from the first AUG in C/EBP
genes were found in the set of genes affected by overex- mRNA, has been shown to interact with the SWI/SNF
pression of wild-type or mutant cyclin D1. Furthermore, ATPase/helicase chromatin-remodeling complex (Ko-
using KS in a data mining exercise with the cyclin D1 wenz-Leutz and Leutz, 1999). Thus, it is conceivable
expression signature in additional prostate, lung, and that this activity, usually involved in gene activation, is
tumor cell databases, they consistently observed coex- actually involved in repression of certain target gene
pression of the transcription factor CCAAT enhancer promoters. Alternatively, C/EBP is acetylated at a
binding protein (C/EBP)  across more than 500 human unique lysine motif within its DNA binding domain. Re-
tumors and cell lines. C/EBP is a member of the basic cruitment of HDAC1 by Stat5 has been shown to lead
leucine zipper family of transcription factors. Encoded to C/EBP deacetylation, increased DNA binding, and
by an intronless gene, cebpb is expressed as several activation of transcription (Xu et al., 2003). Interestingly,
distinct protein isoforms whose expression is regulated cyclin D1 has been reported to interact with both histone
deacetylases, such as HDAC3, and histone acetylasesby the differential use of a number of in-frame translation
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such as P/CAF and SRC1 (reviewed in Coqueret, 2002) TFIIS and GreB: Two Like-Minded
depending on the promoter context, so it will be critical Transcription Elongation Factorsto determine the acetylation status of both C/EBP and
histones on cyclin D1 target gene promoters. A third with Sticky Fingers
important question is why should LIP activate these
target genes? Does it merely displace or antagonize the
transcriptional activity of the bound LAP isoforms? LIP
How the structurally distinct transcription factor TFIIShas been reported to exhibit an increased DNA binding
from eukaryotes and its bacterial counterpart GreBaffinity relative to the LAP isoforms of C/EBP. Does
act to convert their cognate RNA polymerases intothis then imply that there is a reciprocal relationship
ribonucleases has been a longstanding question.between cyclin D1 and LIP expression in cancer? In
Now, two new structures of these factors bound tobreast cancers, LIP was reported to be predominantly
their respective RNA polymerases (Opalka et al. andoverexpressed in ER-negative tumors (Milde-Langosch
Kettenberger et al. [this issue of Cell]) suggest howet al., 2003; Zahnow et al., 1997), while cyclin D1 is usually
they accomplish this feat.elevated in ER-positive tumors. Curiously, overexpres-
sion of the translation initiation factor eIF4e has been
shown to increase cyclin D1 expression, while decreased Eukaryotic TFIIS (also known as SII) and its bacterial
expression of eIF4e and eIF2 has been correlated with counterpart GreB are unique among all transcription
increased LIP expression (Calkhoven et al., 2000). How- factors: they are the only known transcription factors
ever, other mechanisms involving both gene amplifica- capable of restarting arrested RNA polymerases (Wind
tion and transcriptional activation are involved in the and Reines, 2000; Uptain et al., 1997). TFIIS is expressed
overexpression of cyclin D1 in cancer. A more thorough ubiquitously in eukaryotes, where it acts specifically to
examination of the mechanisms regulating the expres- reactivate arrested RNA polymerase II to ensure efficient
sion of different C/EBP isoforms and their activities synthesis of mRNA. GreB performs a similar task in
on different target gene promoters is, however, clearly bacteria.
warranted. Finally, what are the functions of the specific The tendency to arrest is an inherent property of RNA
cyclin D1 target genes identified in this study in the polymerases. Upon arrest, an RNA polymerase stops
etiology of cancer? Thus, while numerous interesting transcribing, refuses to budge even in the presence of
questions remain to be answered, the future for combin- sufficient concentrations of ribonucleoside triphos-
ing molecular genetic and data mining approaches to phates to support further transcript elongation, and
discover novel interactions and pathways in human can- clings tenaciously to its DNA template and nascent tran-
cer appears bright. script, presenting a potential impediment to other RNA
polymerases.
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